Evidence map›Paper›PMID 41597264›Full record

ArticleCells2026

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways.

Vanshika Garg, Raphael N H M Hofmann, Moazzam Saleem, Amin Mirzaiebadizi, Ghazaleh Sadat Hashemi, Tooba Hameed, Bahareh Jooyeh, Silke Pudewell, Mehrnaz Mehrabipour, Niloufar Mosaddeghzadeh and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vanshika GargInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.
Raphael N H M HofmannInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.
Moazzam SaleemInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.ORCID 0000-0001-8592-316X
Amin MirzaiebadiziInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.ORCID 0000-0002-3340-586X
Ghazaleh Sadat HashemiInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.
Tooba HameedInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.
Bahareh JooyehInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.
Silke PudewellInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.ORCID 0000-0002-4653-7263
Mehrnaz MehrabipourInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.
Niloufar MosaddeghzadehInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.
Roland P PiekorzInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.
Mohammad Reza AhmadianInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.ORCID 0000-0002-2034-8894

Funding

Deutsche Forschungsgemeinschaft AH 92/8-3the European Network on Noonan Syndrome and Related Disorders (NSEuroNet) 01GM1602B
6 · The paper itself

Abstract

The oncogene KRAS drives tumor growth by activating pathways such as MAPK and PI3K-AKT in a constitutive manner. Although direct KRAS inhibitors exist, they are often limited in clinical use due to therapeutic resistance and toxicity. Therefore, alternative combinatorial therapeutic strategies are urgently needed. This study examined the knockout of five KRAS-related proteins-galectin-3 (GAL3), phosphodiesterase delta (PDEδ), nucleophosmin (NPM1), IQ motif-containing GTPase-activating protein 1 (IQGAP1), and SHOC2-using CRISPR-Cas9 in adenocarcinoma cell lines harboring the KRAS(G12V) oncogenic mutation, as well as in the noncancerous HEK-293 cell line. These proteins act as critical modulators that regulate KRAS activity, cellular localization, and that of its downstream signaling components. We analyzed the downstream activation of ERK and AKT kinases and evaluated subsequent cancer cell proliferation. Knockout of

Indexed as

CarcinogenesisProto-Oncogene Proteins p21(ras)Signal TransductionCell Line, TumorCell ProliferationGalectin 3HEK293 CellsHumansNuclear ProteinsNucleophosminPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktras GTPase-Activating ProteinsGalectin 3IQ motif containing GTPase activating protein 1KRAS protein, humanNPM1 protein, humanNuclear ProteinsNucleophosminPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)ras GTPase-Activating Proteinsaccessory proteinsadenocarcinomaAKTGalectin-3IQGAP1KRAS oncogeneMAPKnucleophosminPDE-deltaSHOC2signal transduction

Identifiers

PMID41597264
PMCPMC12839328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.